Compare GPK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2007 | 2020 |
| Metric | GPK | ABCL |
|---|---|---|
| Price | $11.96 | $11.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $13.08 | $8.40 |
| AVG Volume (30 Days) | 4.4M | ★ 8.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,617,000,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.79 | $2.75 |
| 52 Week High | $23.06 | $12.15 |
| Indicator | GPK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 73.83 |
| Support Level | $9.95 | $3.38 |
| Resistance Level | $12.25 | N/A |
| Average True Range (ATR) | 0.44 | 0.87 |
| MACD | -0.03 | 0.35 |
| Stochastic Oscillator | 80.60 | 87.21 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.